IBCN 2017: Bladder Cancer Pipeline- Next Generation Epigenetic Biomarkers for Bladder Cancer

Lisbon, Portugal (UroToday.com) Wim Van Criekinge from Ghent University, Belgium discussed the role of next generation epigenetic biomarkers in bladder cancer. Epigenetics allows to use one genome for different purposes and integrate intrinsic and environmental signals. Epigenetics drives the etiology of many human diseases. Overall mutational concordance has been applied using MDX platform. AssureMDx for bladder cancer results are pending and next generation epigenetic profiling can be used using whole genome or clinical PCR. There are 25,000 epigenetic genes and numerous other that regulate other genes. MLH1 promoter methylation is a candidate gene of interest as well as PD-L1 (CD274) which regulated by methylation. These 2 genes may have important implications regarding tumor response to chemotherapy as well as immunotherapy agents.

Speaker(s): Wim Van Criekinge, Ghent University, Belgium

Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., at the International Bladder Cancer Network - October 21, 2017- Lisbon, Portugal

Login